Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
VC

NASDAQ · VCYT

Veracyte, Inc.

Healthcare · Biotechnology

$50.01

Down-$2.16 (-4.14%)

Updated Nov 1, 2026, 11:53 AM

SID Score

6.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.34B
P/E ratio
109.61
Dividend yield
0.00%
52-week range
$29.46 – $60.91
Volume
1.02M
Avg. volume
966.7K

Price performance · VCYT

VCYT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

VCYT closed at $50.01 after 20 trading sessions, up 4.91% for the selected period.

Last close
$50.01
Period change
+4.91%
Period low
$43.11
Period high
$52.17
Daily close
View OHLC price history
VCYT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$51.54$51.93$49.65$50.011.02M
Oct 29, 2026$50.82$52.39$49.63$52.171.23M
Oct 28, 2026$50.00$51.79$49.78$50.311.4M
Oct 27, 2026$48.055$52.25$47.33$50.281.81M
Oct 26, 2026$48.24$48.96$47.70$48.20748.11K
Oct 23, 2026$45.87$48.07$45.48$47.93906.01K
Oct 22, 2026$45.98$46.6299$45.29$46.041.2M
Oct 21, 2026$44.17$46.43$43.90$46.22812.33K
Oct 20, 2026$43.91$45.17$43.47$44.791.14M
Oct 19, 2026$43.70$45.01$43.445$43.80725.43K
Oct 16, 2026$45.00$45.75$42.83$43.122.06M
Oct 15, 2026$43.36$45.5799$42.70$44.391.23M
Oct 14, 2026$42.37$43.99$42.20$43.51935.35K
Oct 13, 2026$43.67$44.29$43.035$43.11760.42K
Oct 12, 2026$45.18$45.22$43.29$44.021.15M
Oct 9, 2026$43.705$46.17$43.50$45.23966.61K
Oct 8, 2026$42.50$43.67$41.215$43.601.22M
Oct 7, 2026$44.04$44.21$42.34$43.161.21M
Oct 6, 2026$48.00$48.84$44.0872$44.651.73M
Oct 5, 2026$45.75$47.785$45.00$47.671.29M

Latest VCYT news

The latest Smart Investors Daily articles mentioning VCYT.

Stock researchCompany · Overview

VCYT research

Overview

Company profile and research snapshot.

Company profile

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$46.33
Implied upside
—
Analysts
—
VCYT recent ratings
DateFirmRatingTarget
Sep 15, 2026Freedom Capital MarketsBuy—
Sep 9, 2026UBSBuy—
Aug 4, 2026Morgan StanleyUnderweight—
Aug 4, 2026Stephens & Co.Overweight—
Aug 4, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMOSOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The

Yahoo · Oct 19, 2026

Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysisSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The presentations span treatment selection and risk asse

Yahoo · Oct 16, 2026

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancerSOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA’s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By